阿斯利康将在华投资超1000亿元

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB (15 billion USD) in China by 2030 to expand its pharmaceutical production and R&D capabilities [1] Investment and Expansion - The investment will enhance AstraZeneca's research and development presence in China, including global strategic R&D centers located in Beijing and Shanghai [1] - These centers collaborate with over 500 clinical hospitals and have led numerous global clinical trials in the past three years [1] - The company will upgrade its existing production bases in Wuxi, Taizhou, Qingdao, and Beijing, with plans to announce new production facilities in due course [1] Employment and Economic Impact - Through these investments, AstraZeneca's workforce in China is expected to exceed 20,000 employees [1] - The initiative will create thousands of new jobs within the broader healthcare ecosystem [1]